Richard D. Carvajal, MD; Jeffrey A. Sosman, MD; Jorge Fernando Quevedo, MD; et al.
Carvajal and coauthors conducted a randomized clinical trial to assess the efficacy of selumetinib, a selective, non–adenosine triphosphate competitive inhibitor of the mitogen-activated protein kinase kinase (MEK) enzymes MEK1 and MEK2, among 120 patients with metastatic uveal melanoma.